Erlonat 100mg

Erlonat 100mg tablets consist of active ingredients known as Erlotinib (Generic Tarceva), that is considered as quinazoline derivative and anti-cancer agents that responses as a protein kinase prohibition for EGFR related to tyrosine kinase. Erlonat 100mg is majorly used in the treatment of non-small cell lung cancer and pancreatic carcinoma and also involved to treat various cancers. Erlonat 100mg has especially aimed at the epidermal growth factor receptor tyrosine kinase.

Erlonat 100mg,Erlonat 100mg tablet

USES OF Erlonat

Non-small cell lung cancer:

Erlonat 100mg tablet is indicated as continuance therapy, in patients with long-lasting or metastasis non-small cell lung carcinoma, whose disease has not to get advance after four cycles with platinum-based first-line therapy. Erlonat 100mg is used in this condition only after the failure of one prior chemotherapy regimen. No clinical advantages occur while using Erlonat 100mg with platinum-based compounds like Carboplatin, gemcitabine or cisplatin.

Pancreatic cancer:

Erlonat 100mg (Erlotinib Hydrochloride) tablet is indicated for the treatment concurrently with gemcitabine, gemcitabine is a chemotherapy drug used to treat the cancer of ovary, breast, pancreas, bladder and non-small cell lung cancer. Cisplatin is also a chemotherapic drug used for the treatment of various types of cancer.

Erlonat WORKS

Erlonat 100mg has pharmacological effects like anti-neoplastic activity, which exhibits its action by inhibiting the intracellular phosphorylation of tyrosine kinase related to epidermal growth factor receptor. This EGFR is present on the surface of the tumor cells. Thus results as inhibition causes interfere with signal transduction and lead to cell lysis

In NSCLC:

The usual recommended dosage of Erlonat 100mg tablet is 150mg should be administered as a single dose by taking in an empty stomach for at least one hour earlier or two hours after intake of food. Therapy with Erlonat 100mg should be continued until the disease advanced or undesirable toxicity occurs. It is not confirmed that advancement after the therapy is beneficial or not. 

In pancreatic cancer:

The daily usual recommended dosage of Erlonat 100mg in pancreatic carcinoma is 100mg should be taken on an empty stomach as a single dose. In this condition, Erlonat 100mg tablet is combined with gemcitabine.

Dosage adjustment:

In case of patients suffered from pulmonary symptoms like dyspnea, fever, cough, or any other conditions, Erlonat 100mg tablet treatment should be discontinued. In interstitial lung disease: To avoid the Erlonat 100mg therapy. In case of gastrointestinal perforation or hepatic failure: Postpone or discontinue the Erlonat 100mg treatment. If diarrhea occurs during the therapy, substitute with loperamide for managing this condition. If dosage reduction is necessary then the dose of Erlonat 100mg reduced into 50mg. Dose reduction is essential in the condition, while concomitant of Erlonat 100mg with strong CYP3A4 inhibitors like atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, voriconazole, grapefruit juice, etc. Dosage elevation occurs in case of concurrent use of Erlonat 100mg tabletwith strong CYP3A4 inducers like rifampin, rifampicin, anti-convulsants etc. The dosage should be increased by 50mg. In chain smoking conditions, increase the dose of Erlotinib into 50mg at two intervals to a higher dose of 300mg. Then the dose is suddenly reduced to 100mg or 150mg in discontinuation of smoking. Erlonat 100mg should not be administered with gastric regulators drug, like proton pump inhibitors or H2 receptor antagonist. In H2 receptors antagonist: Administer Erlonat 100mg at least 10 hours after or 2 hours before H2 receptors antagonist. In proton pump inhibitors: Do not use concurrently if possible.

PHARMACOKINETICS

The peak plasma concentration-time reaches at 4 hours after drug intake After an oral administration of Erlonat, causes 60% of oral bioavailability. Increased by meals to 100%. The solubility of Erlotinib is depended upon pH level. If solubility decreases then lead to increase pH levels. Smoking should be avoided during the treatment with Erlonat, causes decreasing the exposure of Erlotinib. The apparent volume of distribution of Erlotinib is 232L Human protein binding to Erlotinib is occurs as 93%. The metabolism of Erlotinib is occurred by CYP3A4 The route of elimination of Erlotinib metabolites occurs via; Feces: 83%; urine: 8% half-life period of Erlotinib is 36.2 hours.

WARNING AND PRECAUTIONS

Pulmonary toxicity: Interstitial lung disease and other pulmonary toxicity conditions, Avoid the treatment with Erlonat 100mg Renal failure: Frequent monitoring of renal function or serum electrolytes occurs or avoids the treatment. Bullous & exfoliative skin disorders Myocardial infarction or Ischemia Cerebrovascular accident Ocular disorder Elevation of bleeding while concurrent use with warfarin Hemolytic anemia or thrombocytopenia In pregnancy condition In all these conditions, treatment using with Erlonat 100mg should be avoided. Hepatic failure: Hepatic function should be periodically monitored, or otherwise discontinue the therapy with Erlonat. Gastrointestinal perforation: In this condition, discontinue the Erlonat 100mg therapy permanently. This condition occurs due to concurrent use of Erlonat 100mg with NSAIDS, anti-angiogenic drugs, corticosteroids, taxane-based chemotherapy or other drugs, etc.

SOME INTERACTION WITH SOME OTHER DRUGS

Co-administration of Erlonat 100mg with midazolam causes decreasing the AUC of CYP3A4 substrate. Drugs involved in alteration of pH levels causes variation in the solubility of Erlotinib. Avoid concomitant use of gastric regulators with Erlonat. Avoid concomitant use of warfarin with Erlonat, causes increasing the bleeding condition. Co-administration of Erlonat 100mg with CYP3A4 strong inhibitors like ketoconazole causes increasing Erlotinib exposure. Erlonat 100mg concomitant with statins drugs (lipid-lowering drug), causes increasing the concentration of these drugs (rosuvastatin, simvastatin or atorvastatin). Erlonat 100mg concurrently used with ciprofloxacin, CYP3A4 & CYP1A2 inhibitor causes elevation of exposure of Erlotinib tablets. CYP3A4 strong inhibitors like itraconazole, grapefruit juice, ritonavir, indinavir etc CYP3A4 inducers concurrently used with Erlonat 100mg tablets causes decreasing the exposure of Erlotinib. CYP3A4inducers like, rifampin, rifampicin, carbamazepine, phenytoin, etc Cigarette smoking is decreasing the AUC of Erlotinib.

CONTRAINDICATION

In Erlonat 100mg therapy, no contraindication occurs. In some patients, hypersensitivity reactions present due to patients are contraindicated to the ingredients in Erlonat.

MISSED DOSE

In case of the missed dose, patients must consult with the medical oncologist and follow the regular dosing schedule

SIDE EFFECTS

During the therapy, some undesirable effects like; Paronychia, Bullous, blistering and exploitative skin conditions like Stevens Johnson’s syndrome. Gastrointestinal perforation Hepatic failure occurs during monotherapy or combination with other chemotherapy agents Some common side effects: Diarrhea, Fatigue, Anorexia, Pruritus, Acne, Dermatitis, Dry skin, Loss of weight, Paronychia, Cough, Vomiting, Conjunctivitis, Keratoconjunctivitis sicca, Abdominal pain, Stomatitis, Infection, nausea, Bone pain, Alopecia, Anxiety, Neuropathy, Renal disorders, hepatic disorders, ocular disorders, skin, hair and nail disorders.

OVERDOSAGE

In case of overdosage, Erlonat 100mg therapy should be postponed and symptomatic treatment should be recommended.

Contact Details

 Phone : +91-9987711567

 Email :applepharmaceutical@gmail.com

 Email :info@myapplepharma.com